IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated study to Assess the
Efficacy of OC-01 (varenicline) Nasal Spray on signs and symptoms of Dry Eye Disease in
subjects following Corneal Collagen Crosslinking (CXL)